Faculty Collaboration Database

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. Blood 2026 Jul 16;148(3):348-360

Date

03/03/2026

Pubmed ID

41774517

DOI

10.1182/blood.2025031733

Scopus ID

2-s2.0-105041226033 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using data in the Center for International Blood and Marrow Transplant Research Registry from 5 February 2021 to 4 February 2025. Eligible patients (N = 1116) received liso-cel and had ≥1 effectiveness and safety assessment after infusion, including 195 in the second-line setting, 71 with sCNS, and 257 with transformed LBCL. Median age was 71.1 years (range, 21.5-91.2), with 72.3% aged ≥65 years. Within the overall population, 6.6% had an Eastern Cooperative Oncology Group performance status of ≥2, 53.4% had ≥1 comorbidity, and the median number of previous lines of therapy was 3 (range, 1-16). Median study follow-up was 12.6 months (95% confidence interval [CI], 12.5-12.8). Among effectiveness-evaluable patients (n = 1109), objective response rate was 81.2% and complete response rate was 71.3%. Duration of response, progression-free survival, and overall survival rates at 12 months were 60.2% (95% CI, 56.4-63.9), 51.2% (95% CI, 48.0-54.4), and 67.6% (95% CI, 64.5-70.6), respectively. Cytokine release syndrome was reported in 51.0% of patients, with grade ≥3 events in 2.5%. Immune effector cell-associated neurotoxicity syndrome was reported in 26.6% of patients, with grade ≥3 events in 9.2%. The 12-month nonrelapse mortality rate was 6.1% (95% CI, 4.6-7.8). These real-world data reinforce the effectiveness and safety of liso-cel in this broad population of patients with R/R LBCL, including younger patients and those with high-risk disease features.

Author List

Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning M, Egini O, Odstrcil Bobillo MS, Kallam A, Thiruvengadam SK, Lee DC, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I

Authors

Mehdi Hamadani MBBS Professor in the Medicine department at Medical College of Wisconsin
Soyoung Kim PhD Associate Professor in the Data Science Institute department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Female
Granulocyte Colony-Stimulating Factor
Humans
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Neoplasm Recurrence, Local
Recurrence
Treatment Outcome
Young Adult